Description: Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.
Home Page: www.oysterpointrx.com
OYST Technical Analysis
202 Carnegie Center
Princeton,
NJ
08540
United States
Phone:
609 382 9032
Officers
| Name | Title |
|---|---|
| Dr. Jeffrey Nau MMS, Ph.D. | Pres, CEO & Director |
| Mr. Daniel Lochner M.B.A. | CFO & Chief Bus. Officer |
| Mr. George Donato M.B.A. | Sr. VP of CMC & Operations |
| Dr. Eric Carlson Ph.D. | Chief Scientific Officer |
| Arty Ahmed | VP of Investor relations |
| Mr. Barry Rosenfeld J.D. | Sr. VP & Gen. Counsel |
| Ms. Raegan A. McClain CCEP, J.D., L.L.M. | Chief Compliance & Privacy Officer |
| Ms. Karen Castillo-Paff | VP of Communications & PR |
| Mr. Dave Benadon | Chief HR Officer |
| Ms. Loni Da Silva M.S. | Sr. VP of Regulatory Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3909 |
| Price-to-Sales TTM: | 15.2699 |
| IPO Date: | 2019-10-31 |
| Fiscal Year End: | December |
| Full Time Employees: | 303 |